One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer ...

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer. Postsurgical treatment with androgen deprivation therapy and Erleada ...

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...

This medication is a beneficial addition to your prostate cancer treatment plan — but it doesn’t come without risks. Here’s how to stay ahead of potential side effects. If you’ve been diagnosed with ...

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

Clinical Trials—Real-World Data to Build a Future for Our Patients In the article that accompanies this editorial, Kwak et al 6 demonstrate using individual patient data from randomized trials that ...